WASHINGTON -- Research presented here at the annual Liver Meeting sponsored by the American Association for the Study of Liver Diseases included a better combination for severe alcoholic hepatitis, ...
When the use of prophylactic granulocyte-colony stimulating factor (G-CSF) to reduce febrile neutropenia (FN) was decreased in patients receiving chemotherapy for breast cancer, it led to a more than ...
Efficacy comparison of anthracycline and taxane when added to immune checkpoint inhibitor in neoadjuvant chemotherapy of triple negative breast cancer: Clinical evidence from size-reduction ...
Incidence and risk factors for venous thromboembolism after CAR T-cell therapy: A systematic review and meta-analysis. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...
Spectrum Pharmaceuticals Inc. celebrated a long-awaited win with the U.S. FDA’s approval late Sept. 9 of novel G-CSF drug eflapegrastim, cleared for use in chemotherapy-induced neutropenia nearly four ...
A study published in the Journal of Cannabis Research examined the effect of granulocyte colony-stimulating factor (G-CSF) on brain recovery following traumatic brain injury (TBI). The findings showed ...
WASHINGTON — Adding granulocyte-colony stimulating factor (G-CSF) to steroid therapy can improve 90-day survival for patients with severe alcoholic hepatitis (SAH), researchers from India reported.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results